Alcohol addiction is characterized by broad and persistent changes in brain function, but the underlying neural adaptations remain largely unknown. In this issue of Neuron, Laguesse et al. (2017) describe a neural mechanism through which long-term alcohol exposure induces structural and synaptic adaptations that promote excessive alcohol use.
The World Health Organization (2014) estimates that alcohol use causes 5.9% of all deaths worldwide and 5.1% of the global disease burden measured as disability-adjusted life years. Combine these numbers with a paucity of effective treatment options, and it should be obvious that alcohol use disorders, or simply ''alcohol addiction,'' are an area of great unmet medical needs.
Advances in neuroscience hold the hope of addressing these unmet needs, and the past decade has indeed seen a remarkable growth in basic research on the neural mechanisms behind alcoholrelated behaviors. The promise that this research would translate into novel pharmacotherapies has, however, not yet materialized. In the United States, the most recent approval of a pharmacotherapy for alcohol addiction was in 2004. At that time, approval of acamprosate, a medication with largely unknown mechanisms of action, brought up the number of approved alcohol addiction medications to three. None have since followed. To make matters worse, currently marketed therapeutics have only achieved marginal clinical penetration, in part due to limited efficacy.
It should therefore be clear that there is both a need and an opportunity for innovative target identification strategies in search of novel pharmacotherapies for alcohol addiction. Historically, blockade or activation of G-protein-coupled receptors or modulation of neurotransmitter transporter activity have been the mechanism classes that have yielded most successful psychiatric medications. This pipeline has, however, dried up lately, and psychiatric drug development is facing a major crisis (Hyman, 2012) . It is clearly time to explore molecular mechanisms that have broader actions on neuronal function and that have not previously been considered as candidate drug targets. The case for this is perhaps the strongest in addictive disorders, where drug exposure itself leads to a broad spectrum of lasting changes in neuronal function.
Alcohol addiction is a prime example of this. In this condition, prolonged exposure of the brain to alcohol is a key factor behind the emergence of the clinical syndrome (Heilig et al., 2010) . Rather than targeting mechanisms that mediate acute rewarding properties of alcohol in the normal brain, successful novel therapeutics may therefore need to target the lasting changes in brain function, or ''neuroadaptations'' that evolve with prolonged brain alcohol exposure. Among these neuroadaptations, processes underlying altered synaptic strength in key nodes of motivational circuitry offer particularly attractive target mechanisms.
The paper by Laguesse et al. (2017) in this issue of Neuron elegantly focuses on this type of neuroadaptive process and does so in a manner that is likely to maximize its translational potential. For their discovery work, Laguesse et al. (2017) used a mouse model in which intermittent availability of alcohol leads to escalation of voluntary alcohol intake, bringing brain alcohol exposure to levels that promote alcohol-induced neuroadaptations. Before carrying out their discovery work, Laguesse et al. (2017) allowed mice to maintain their escalated consumption for 2 months, a duration that was sufficient for important neuroadaptations to take place. This made it possible for the researchers to direct their molecular screening to processes that should have the best prospect of being clinically relevant.
To identify candidate mechanism mediating alcohol-induced neuroadaptations, Laguesse et al. (2017) used RNA sequencing (RNA-seq) and screened for differential gene expression. They focused on the nucleus accumbens (NAc), a key node of brain circuitry that is critically important for goal-oriented approach behavior, a process thought to go awry in the addicted brain (Koob and Volkow, 2010) . Synaptic remodeling in this structure is centrally positioned to promote pathologically increased motivation to seek and consume alcohol. In carrying out their discovery experiments, Laguesse et al. (2017) were also able to capitalize on a major advance in the understanding of alcohol-induced signaling recently made by their own laboratory. This work has shown that binge-like alcohol consumption activates signaling by the mTORC1 complex in the NAc and that this activation is critically important for induction of synaptic plasticity by alcohol (Beckley et al., 2016) . In the present paper, Laguesse et al. (2017) were therefore able to guide their RNA-seq screen by focusing on transcripts that were elevated by alcohol drinking in a manner sensitive to rapamycin, a blocker of the mTORC1 complex.
Among their RNA-seq hits, Laguesse et al. (2017) prioritized the transcript for Pro-SAP2-interacting protein 1, or ProSAPiP1, for functional validation. This is an intriguing candidate in search of mechanisms that mediate structural alcohol-induced plasticity, because it has previously been shown to localize to excitatory spines and their postsynaptic densities, where it is part of the scaffolding machinery (Wendholt et al., 2006) . ProSAPiP1 is therefore positioned at the center of processes that have the potential to mediate the progression from functional to structural plasticity, thereby ''locking in'' a pathological motivational state. As would be expected given its dependence on mTORC1 activity, Laguesse et al. (2017) were able to show that the increase in ProSAPiP1 induced by alcohol was not the result of its increased transcription, but rather of increased translation of existing mRNA transcripts.
Previously, research has provided data on the role of ProSAPiP1 in structural plasticity within the hippocampus. ProSAPiP1 was found to interact with SPAR, a Rapspecific GTPase-activating protein (RapGAP) (Wendholt et al., 2006) . SPAR is, in turn, known to interact with the guanylate kinase-like domain of the postsynaptic density protein 95 (PSD-95) and has been previously shown to localize to dendritic spines, where it promotes enlargement of spine heads and synapse formation. The effects of SPAR on spine morphology in the hippocampus depend on the RapGAP and actin-interacting domains, implicating Rap signaling in the regulation of postsynaptic structure (Pak et al., 2001 ).
In their present work, Laguesse et al. (2017) were able to demonstrate that ProSAPiP1 plays a similar role in the NAc. Laguesse et al. (2017) showed that, similar to the hippocampus, ProSAPiP1 interacts with SPAR. Overexpression of ProSAPiP1 in the NAc resulted in an increase in filamentous (F-) at the expense of globular (G-) actin. In contrast, knockdown of ProSAPiP1 expression had the opposite effect, suggesting that ProSAPiP1 promotes a rearrangement of the cytoskeleton by influencing the equilibrium between G-and F-actin. Furthermore, electrophysiology experiments point to the possibility that these structural changes alter glutamatergic transmission in Nac medium spiny neurons (MSNs) in a very interesting way. The findings of the present study suggest that ProSAPiP1-dependent rearrangement of postsynaptic densities promotes insertion of calcium-permeable, GluA2-lacking AMPA receptors ( Figure 1A ).
More importantly, Laguesse et al. (2017) demonstrated that knockdown of ProSAPiP1 expression in the NAc also prevented the shift toward F-actin that resulted from chronic intermittent exposure of the brain to alcohol. The knockdown also prevented the increase in dendritic spine area that resulted from escalated alcohol consumption and prevented membrane insertion of GluA2-lacking AMPA receptors by chronic alcohol exposure ( Figure 1B) . Insertion of GluA2-lacking, calcium-permeable AMPA receptors has not been studied in detail in models of alcohol addiction, but it has previously been shown to play a critical role in stimulant addiction models, where it, for instance, mediates the (A) Hypothetical scheme of the role ProSAPiP1 plays in structural and synaptic plasticity. Rap activity is terminated by SPAR, which catalyzes the hydrolysis of Rap-bound GTP to GDP. Interaction of ProSAPiP1 with SPAR promotes the formation of Factin and the enlargement of spine heads. Actin polymerization at the spine heads contributes to the membrane insertion of calcium-permeable, GluA2-lacking AMPAR. (B) ProSAPiP1 knockdown increases the density of thin spines. (C) An alcohol-dependent increase in the expression of ProSAPiP1 promotes F-actin formation, increases the density of mushroom spines, and promotes the insertion of GluA2-lacking, calcium-permeable AMPA receptors. increase in motivation to obtain drug that progressively emerges following forced abstinence, called ''incubation of craving'' (Conrad et al., 2008) . Together, these data elegantly bring full circle the demonstration that ProSAPiP1 plays a causal role in alcohol-induced structural plasticity within the NAc.
All this molecular work is highly compelling. In the end, however, behavioral consequences are key to establishing the functional role of a mechanism in an addictive disorder and to validating its potential as a target for therapeutics. The testable prediction from the molecular work in the present study was that blockade of ProSAPiP1 expression in the NAc would reduce alcohol self-administration following its escalation and that this would be the result of preventing an increase in the reward value of alcohol ( Figures 1B and 1C) . Both those predictions are indeed demonstrated to be correct by Laguesse et al. (2017) , bringing their target identification and validation full circle.
Given the ubiquitous role of spine morphology rearrangements, it is very encouraging and perhaps somewhat surprising that these effects appear to be behaviorally specific. This suggests that an alcohol-induced increase in ProSAPiP1 expression and function is a phenomenon that operates outside the range of normal synaptic physiology.
The latter issue goes to the heart of assessing the potential of these findings to open new avenues toward developing novel therapeutics. A decade ago, most seasoned drug developers would have brushed aside this type of mechanism as a candidate target for medications. Among the arguments would have been that its actions are too broad and that molecules targeting it would therefore be expected to have an unacceptable safety and tolerability profile. But if, as the current findings suggest, this mechanism is only engaged as a result of pathological neuroadaptations, then there may also be hope of selectively targeting it for treatment. In fact, the canonical inhibitor of mTOR signaling, rapamycin, has long been used clinically for its immune-suppressant properties and has a therapeutic window in which these effects can be obtained in the absence of unacceptable toxicity.
In that context, an important question that remains is what is upstream of alcohol-induced mTORC1 signaling and the resulting cytoskeleton rearrangement. The mTORC1 signaling complex functions as an integration point for an exceedingly complex set of cellular processes, including nutritional status and growth factor activity (Lipton and Sahin, 2014) . This rich signaling landscape offers challenges for research but may also bring with it opportunities for identifying additional druggable targets. Hopefully, innovative research, such as that by Laguesse et al. (2017) , can help persuade the pharmaceutical industry to re-engage in developing therapeutics for psychiatric disorders and addiction.
